ESR1 and breast carcinoma: ET is the mainstay treatment in ER+ breast cancer (24), and these treatment options include selective estrogen receptor modulators (SERMs), aromatase inhibitors (AI), selective estrogen receptor degraders (SERDs), and selective estrogen receptor covalent antagonists (SERCAs).